C反应蛋白与白蛋白比值在泌尿系恶性肿瘤中的研究进展  

Research Progress of the Ratio of C-Reactive Protein to Albumin in Malignant Tumors of Urinary System

作　　者：玉买尔艾力江·开赛尔 马彬[1] 王晨宇[2] 

机构地区：[1]新疆医科大学第二附属医院泌尿外科,新疆 乌鲁木齐 [2]新疆维吾尔自治区人民医院泌尿外科,新疆 乌鲁木齐

出　　处：《临床医学进展》2023年第12期19381-19386,共6页Advances in Clinical Medicine

摘　　要：肿瘤本身是一种慢性消耗疾病,而慢性炎症会引起免疫缺失、促进血管生成、营养不良等,从而加快肿瘤生长。血清C反应蛋白与白蛋白比值(C-reactive protein/albumin, CRP/Alb)作为炎症及营养联合指标,是近年来备受关注的新型炎症标志物。近年来,陆续有研究分析指出CRP/Alb作为各种癌症的预后预测新型生物标志物,包括结直肠癌、胃癌、胆囊癌及非小细胞肺癌等。但CRP/Alb在泌尿系肿瘤中的研究相对较少,本文就CRP/Alb在泌尿系恶性肿瘤中的研究进展进行综述。Tumor itself is a chronic wasting disease, and chronic inflammation can cause malnutrition, im-mune deficiency, promote angiogenesis, etc. thus accelerating tumor growth. The ratio of serum C-reactive protein to albumin (CRP/Alb), as a joint indicator of inflammation and nutrition, is a new inflammatory marker that has attracted much attention in recent years. In recent years, studies have pointed out the application of CRP/Alb as a prognostic biomarker for various cancers, includ-ing gastric cancer, colorectal cancer, non-small cell lung cancer, gallbladder cancer, etc. However, there are relatively few studies on CRP/Alb in urinary tumors. This article reviews the studies on CRP/Alb in malignant tumors of urinary system.

关 键 词：C反应蛋白 白蛋白 泌尿系肿瘤 预后 

分 类 号：R73[医药卫生—肿瘤]